It is the most recognized mushroom in the world with its scarlet cap, white spots, and fairy-tale silhouette. It has been a staple of Christmas cards and Mario games for decades. It has also, for most of that time, been misclassified.

Western science filed Amanita muscaria, the fly agaric, under a single label of poisonous. That label was not entirely wrong, but it is incomplete. Across traditional plant medicine, neuroscience, and the growing community of careful self-experimenters, a different picture is emerging: a mushroom with a real, if still largely unexplored, case for therapeutic use.
Pain relief. Neuroprotection. Sleep. Anxiety. The evidence is early and the risks are real, but the research questions are finally being asked—so let’s dig in.
How muscimol works
Most psychedelics work through serotonin. Psilocybin, LSD, and DMT all hit the same receptor in the brain, producing the flooded, hyperconnected states that have come to define the modern psychedelic renaissance. Muscimol, the principal active compound in Amanita muscaria, does none of that.
Muscimol works on the brain's GABA system. This is the same system targeted by alcohol, benzodiazepines, and barbiturates. Where psilocybin “turns the volume up,” muscimol turns it down, acting as a brake on the central nervous system with effects concentrated deep in the brain's processing centers. The result, as longtime users consistently describe it, is something quieter and more inward than a psilocybin trip. Sedative, dreamlike, and felt in the body.
So while the GABA system governs pain modulation, anxiety, sleep architecture, and neuroprotection, muscimol, it turns out, touches all of them.
What the shamans already knew
The ethnopharmacological record on fly agaric is ancient and consistent. Linguistic analysis of North Asian languages from around 4000 BCE suggests the roots of the words for "drunkenness" and Amanita muscaria were one and the same. Among the Koryak people of the Kamchatka Peninsula of eastern Russia, it was used topically—pounded into a soft, moist paste for joint pain and inflammation—and orally, for anxiety relief and as a stimulant for endurance. Mid-19th century accounts describe Koryak men reporting dramatically increased stamina after consuming dried fly agaric, capable of working through what felt like three men's labor in a single day.
Across Siberia, Scandinavia, and Eastern Europe, the therapeutic applications are aligned: pain relief, anti-inflammatory, anti-anxiety, sleep aid. The tradition never stopped, but the research never started.
One piece of preparation knowledge that turns out to be scientifically significant is that Siberian shamans dried their mushrooms over fire before consumption. Drying and heating trigger decarboxylation—a process that converts ibotenic acid, the mushroom's more toxic compound, into muscimol. The conversion is partial, not complete, but it meaningfully shifts the ratio in muscimol's favor. The shamans were optimizing their extract without a laboratory. Modern users who neglect this step and eat Amanita muscaria raw encounter something quite different: sweating, nausea, disorientation. The preparation is the medicine.
A peer-reviewed study published in Roczniki Kulturoznawcze (Annals of Culturology) confirmed what anthropologists had long documented: that the mushroom was used among the Koryak for a range of therapeutic purposes including pain management, skin conditions, rheumatism, and nervous system disorders, and that folk medicine use persists in the community today.
Muscimol and pain research
The most developed clinical case for muscimol centers on pain, specifically neuropathic pain, one of medicine’s most treatment-resistant conditions.
Neuropathic pain affects somewhere between 3 and 17 percent of the general population at any given time. It arises from damage or dysfunction in the nervous system itself and responds poorly to conventional pain relievers. A 2023 systematic review analyzing the results of 22 studies concluded that muscimol can effectively ease multiple forms of neuropathic pain, with onset in as few as 15 minutes and duration of at least three hours.
A 2023 analysis of 684 people discussing Amanita muscaria use across social media found that pain relief was the primary reason women sought out the mushroom, with many turning to tinctures as their preferred preparation. The community experience aligns with the mechanism: GABA-A receptor activation suppresses the hyperactive neural firing that characterizes neuropathic states.
A 2025 thematic analysis of r/AmanitaMuscaria by Matthews & Sharma found pain relief to be among the most prominent reasons users sought out the mushroom, with many describing a reduction in chronic aching and physical tension that had resisted conventional treatment. Tea was the most common preparation method among those seeking physical relief.
Additional animal studies have documented muscimol’s protective effects against systemic inflammatory responses, and Psyched Wellness has released preliminary data conducted by the National Research Council of Canada suggesting their AME-1 extract can inhibit human mast cell activation; the mechanism behind inflammatory skin conditions like atopic dermatitis and hives. The NRC has not endorsed the findings, and no peer-reviewed publication has followed to date, but the Koryak pounded fly agaric into a paste for exactly the kind of joint inflammation that comes from surviving a Siberian winter.
Muscimol and neuroprotection
The least-discussed angle in the Amanita muscaria story is perhaps the most scientifically striking.
Multiple studies have found that muscimol suppresses essential tremor without impairing speech or coordination. In Parkinson’s patients, microinjections of muscimol have reversed tremor symptoms. In Alzheimer's research, low doses of muscimol have been shown to significantly improve spatial learning and memory in rat models, reversing cognitive deficits by as much as 90%. In Huntington's disease, a double-blind clinical trial found muscimol did not improve motor or cognitive function broadly, though it did reduce chorea (involuntary, irregular jerking movements) in the most severely affected patient; a partial signal that GABAergic activity plays some role in the condition's symptom profile. A 2019 in vitro study evaluating standardized Amanita extract (high in muscimol) found no standalone neurotoxic effects, and significant neuroprotective and antioxidant activity under induced neurotoxicity conditions, across rat brain microsomes, mitochondria, and synaptosomes.
Free radical scavenging, mitochondrial protection, and modulation of nerve cell overstimulation are all mechanisms well-documented in GABA pharmacology and none of this should be surprising, in retrospect. But what is surprising is how thin the research pipeline remains. Muscimol was labeled a poison early, dropped from most programs, and essentially forgotten as a therapeutic subject.
According to Psyched Wellness CEO Jeff Stevens, Professor David Nutt—a neuropsychopharmacologist and Psyched Wellness board member—commissioned a review that identified more than 3,200 scientific papers dealing with muscimol, GABA-A receptors, ibotenic acid, and Amanita muscaria.
Interestingly, a synthetic drug derived from muscimol has received more research attention than muscimol itself. That drug, Gaboxadol, was developed by pharmaceutical companies and advanced all the way into large-scale clinical trials for insomnia before being pulled due to inconsistent results. The original compound it was based on (muscimol) was in many ways more interesting. Researchers just weren't looking at it.
Muscimol, sleep, and anxiety
The current wave of Amanita users includes the careful microdosers logging their protocols across forums and the wellness seekers who found psilocybin too loud and came looking for something quieter. For them, sleep and anxiety are the most commonly cited benefits.
In the 2025 thematic analysis mentioned earlier of 998 posts and 9,542 comments from r/AmanitaMuscaria, sleep improvement was found to be the single most common reason users sought out the mushroom with recurring descriptions of deeper, more vivid sleep and a calmer baseline anxiety; often from users who had tried and abandoned pharmaceutical sleep aids. Adverse effects, where reported, were minimal and largely self-limiting.
The mechanism supports it. Animal studies have demonstrated increases in REM sleep frequency and duration—the stage most critical for emotional processing, memory, and learning.
Baba Masha’s large-scale survey of over 3,000 Amanita muscaria microdosers found that 73% of participants with sleep disorders reported positive outcomes, and 87% of those with depression or chronic fatigue reported improvement. These are survey figures, not clinical results, but when over 3,000 people report the same thing in the same direction, that’s a signal worth investigating.
At doses typically running 1 to 5 milligrams of muscimol, users describe something closer to a benzodiazepine-adjacent calm than a psychedelic experience, with a significantly lower risk of addiction than long-term benzo use. Whether muscimol can consistently deliver on these effects without tolerance development remains an open research question, but it's a credible one.
The risks of Amanita muscaria
None of this means fly agaric is safe to pick and eat!
The margin between a therapeutic muscimol dose and an unpleasant experience is narrow and poorly characterized. Ibotenic acid content varies significantly between individual mushrooms. There is no standardized wild dose. Improperly prepared or undried specimens can deliver far more ibotenic acid than muscimol, producing the disorientation, nausea, and autonomic effects that gave the mushroom its poisonous reputation. The European Food Safety Authority flagged Amanita muscaria as an emerging risk in 2023, citing concerns about increasingly unregulated commercial availability (gummies, vaporizers, infused pre-rolls) with no standardized dosing or preparation oversight.
Because psilocybin remains federally illegal in the US while muscimol does not, Amanita muscaria has increasingly been marketed as a legal stand-in for psilocybin-containing mushrooms. Products labeled “magic mushroom” gummies or chocolates are frequently muscimol-based rather than psilocybin-based—a distinction that matters enormously, given that the two compounds work through entirely different mechanisms and produce very different experiences. Consumers assuming they’re getting a psilocybin-adjacent product are often getting something closer to a sedative. The confusion is widespread and, in some corners of the market, deliberate.
More importantly: Amanita muscaria shares its genus with some of the most lethal organisms on earth. The death cap (A. phalloides) contains amatoxins lethal at 0.1 to 0.3 mg per kilogram of body weight. Misidentification in the field is not a theoretical risk.
The traditional knowledge around fly agaric was always knowledge about preparation, dose, and context. The Koryak didn’t eat it raw and the shamans didn’t free-dose it without framework. The medicine was inseparable from the method.
A worthy investigation
The story of Amanita muscaria is a story about what happens when a substance gets classified before it is understood.
The poison label arrived before the pharmacology did and the traditional knowledge was dismissed as folklore. The research stopped and for decades, one of the most pharmacologically interesting fungi on the planet sat in the background of textbooks and starring on Christmas ornaments.
The mycology community was skeptical of that dismissal long before the science caught up. So were the Koryak and the communities across Siberia who kept using it. Now, slowly, the clinical literature is beginning to build the case for what those traditions always suggested.
Nothing in this article constitutes medical advice. Amanita muscaria is psychoactive, variable in potency, and should be approached with preparation knowledge and caution.
References & Further Reading
What does Amanita muscaria have to do with Christmas?
4 Routines for Daily Wellness with Functional Mushrooms
van Hecke, O., et al. (2014). Neuropathic pain in the general population. Pain, 155(4). https://pubmed.ncbi.nlm.nih.gov/24291734/
Ramawad, H. A., et al. (2023). Muscimol as a treatment for nerve injury-related neuropathic pain. Korean Journal of Pain, 36(4). https://pubmed.ncbi.nlm.nih.gov/37732408/
Matthews, S. J., & Sharma, P. (2025). Exploring user experiences with Amanita muscaria: A thematic analysis of Reddit online forum discussions. Substance Use & Misuse, 60(7). https://doi.org/10.1080/10826084.2025.2476141
Ordak, M., et al. (2023). Reasons, form of ingestion and side effects associated with consumption of Amanita muscaria. Clinical Toxicology, 61(4). https://pubmed.ncbi.nlm.nih.gov/37112610/
Hsu, D. Z., et al. (2009). Muscimol increases the survival rate and inhibits the inflammatory response in endotoxemic mice. Critical Care. https://doi.org/10.1186/cc8075
Li, Y. H., et al. (2022). The protective effect of muscimol against systemic inflammatory response in endotoxemic mice. Canadian Journal of Physiology and Pharmacology, 100. https://pubmed.ncbi.nlm.nih.gov/35856422/
Tasker, R. R., et al. (1999). Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor. Neurology, 53(2). https://pubmed.ncbi.nlm.nih.gov/10443891/
Oset-Gasque, M. J., et al. (2016). GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease rat model. https://pmc.ncbi.nlm.nih.gov/articles/PMC4797603/
Shoulson, I., et al. (1978). Huntington’s disease: treatment with muscimol. Annals of Neurology, 4(3). https://pubmed.ncbi.nlm.nih.gov/152602/
Kondeva-Burdina, M., et al. (2019). Effects of Amanita muscaria extract on different in vitro neurotoxicity models. Food and Chemical Toxicology, 132. https://doi.org/10.1016/j.fct.2019.110687
Stevens, J. (2021). Harnessing the therapeutic potential of muscimol [Interview]. Technology Networks. https://www.technologynetworks.com/neuroscience/blog/harnessing-the-therapeutic-potential-of-muscimol-349541
Roth, T., et al. (2010). Effect of gaboxadol on patient-reported measures of sleep. Journal of Clinical Sleep Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC2823273/
Vyazovskiy, V. V., et al. (1996). Role of GABA-A receptors in sleep regulation. https://pubmed.ncbi.nlm.nih.gov/8797193/
Leas, E. C., et al. (2024). Need for a public health response to the unregulated sales of Amanita muscaria mushrooms. American Journal of Preventive Medicine, 67(3). https://doi.org/10.1016/j.amepre.2024.05.006
European Food Safety Authority. (2023). Risk associated with the increase in consumption of Amanita muscaria. https://www.efsa.europa.eu/sites/default/files/2024-01/4.3-risk-increase-consumption-amanita-muscaria.pdf
CDC MMWR. (2017). Amanita phalloides mushroom poisonings — Northern California. https://www.cdc.gov/mmwr/volumes/66/wr/mm6621a1.htm
Psyched Wellness Ltd. (2021). Preliminary data: AME-1 extract inhibits human mast cell activation. https://www.newsfilecorp.com/release/100063
Masha, B. (2022). Microdosing with Amanita muscaria. Inner Traditions. Cited via Medical Matters
Wierzbicki, K. (2022). The customs of Siberian Koryaks: The use of fly agaric in Kamchatka folk medicine. Roczniki Kulturoznawcze. https://ojs.tnkul.pl/index.php/rkult/article/view/17866
Chacruna Institute. (2022). Fly agaric: A compendium of history, pharmacology, mythology, and exploration. https://chacruna.net/fly-agaric-amanita-muscaria-traditional-modern-therapeutic-uses/
ICEERS. (2019). Amanita muscaria: Basic info. https://www.iceers.org/en/basic-info/amanita-muscaria-basic-info/